RXi Pharmaceuticals

Marlborough drugmaker Phio Pharmaceuticals is partnering with a Philadelphia biotech on a research collaboration to help evaluate the company’s scientific platform for use in cancer treatment.

A Marlborough company making imaging technology for medical procedures has outgrown its space at the Marlborough Technology Center, but another tenant is renewing.

Marlborough startup drugmaker Phio Pharmaceuticals has changed its name, CEO and model as it attempts to become a cancer therapeutics firm.

Life sciences company Phio Pharmaceuticals has extended its lease in the Marlborough Technology Center at 257 Simarano Drive.

Marlborough biotech Phio Pharmaceuticals CEO Geert Cauwenbergh is retiring, and the company's chief operating officer is taking his place.

A UMass Medical School professor and Nobel Prize winner knew of a Chinese researcher's work on gene-edited babies before that work became public, according to the Associated Press.

Marlborough startup drugmaker RXI Pharmaceuticals now has a runway extending into 2020 as the company continues to reinvent itself and rebrand into a pharmaceutical firm focused on fighting cancer.

Marlborough's fledgling drugmaker RXi Pharmaceuticals is hoping to raise about $15 million via a public offering in which it hopes to sell at least 21.4 million of its shares.

Despite reporting just $58,000 in second-quarter revenues, Marlborough drugmaker RXi Pharmaceuticals was able to significantly reduce its net loss, reduce its cash burn and extend its runway.

Marlborough drugmaker RXi Pharmaceuticals is set to receive nearly $250,000 in grant funds for a collaboration with Cambridge-based BioAxone BioSciences.